RELATIONSHIP BETWEEN PHARMACOKINETICS AND ANTI-DRUG ANTIBODY STATUS OF ABP 501, A BIOSIMILAR CANDIDATE TO ADALIMUMAB

被引：4
|
作者：
Kaur, P. [1 ]
Chow, V. [1 ]
Zhang, N. [1 ]
Markus, R. [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.4763
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0167
引用
收藏
页码：714 / 714
页数：1
相关论文
共 50 条
  • [21] Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels
    Ogric, Manca
    Zigon, Polona
    Drobne, David
    Stabuc, Borut
    Sodin-Semrl, Snezna
    Cucnik, Sasa
    Praprotnik, Sonja
    IMMUNOLOGIC RESEARCH, 2018, 66 (06) : 726 - 736
  • [22] Therapeutic Drug Monitoring of the Adalimumab Biosimilar (AMJEVITA™, Adalimumab-atto) Using Originator Adalimumab and Anti-Adalimumab Antibody Assays
    Bastidas, Monique
    Yeo, Lythou
    Magpantay, Susie
    Scott, Judah
    Zikry, Mike
    Galdamez, Wayne
    Yang, Jane
    Chun, Kelly
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 937 - 938
  • [23] Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service
    Nice, R.
    Chanchlani, N.
    Green, H.
    Bewshea, C.
    Kennedy, N.
    Ahmad, T.
    Goodhand, J.
    McDonald, T.
    Perry, M.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S018 - S019
  • [24] POSITIVITY THRESHOLDS OF TOTAL INFLIXIMAB AND ADALIMUMAB ANTI-DRUG ANTIBODY ASSAYS AND IMPACT IN CLINICAL PRACTICE
    Nice, Rachel
    Chanchlani, Neil
    Kennedy, Nicholas A.
    Green, Harry D.
    Lin, Simeng
    Gordon, Claire
    Chee, Desmond
    Hamilton, Benjamin
    Bewshea, Claire
    Goodhand, James
    Ahmad, Tariq
    McDonald, Timothy
    Perry, Mandy
    GUT, 2021, 70 : A103 - A103
  • [25] Neutralization Activity of Anti-drug Antibodies Against a Biotherapeutic Can Be Predicted from a Comprehensive Pharmacokinetics, Pharmacodynamics, and Anti-drug Antibody Data Analysis
    Weifeng Xu
    Brian Maas
    Brad Roadcap
    Aparna Swarup
    Thomas Steinmetz
    Linlin Luo
    Marina Ichetovkin
    Sandra Wood
    Faye Vazvaei-Smith
    Andrew Wen-Tseng Lee
    Kalpit Vora
    Roy Helmy
    The AAPS Journal, 24
  • [26] Neutralization Activity of Anti-drug Antibodies Against a Biotherapeutic Can Be Predicted from a Comprehensive Pharmacokinetics, Pharmacodynamics, and Anti-drug Antibody Data Analysis
    Xu, Weifeng
    Maas, Brian
    Roadcap, Brad
    Swarup, Aparna
    Steinmetz, Thomas
    Luo, Linlin
    Ichetovkin, Marina
    Wood, Sandra
    Vazvaei-Smith, Faye
    Lee, Andrew Wen-Tseng
    Vora, Kalpit
    Helmy, Roy
    AAPS JOURNAL, 2022, 24 (06):
  • [27] Preventing Crohn's Disease recurrence after resection with adalimumab: Role of drug and anti-drug antibody levels
    Wright, E.
    Kamm, M.
    Selvaraj, F.
    Princen, F.
    De Cruz, P.
    Hamilton, A.
    Ritchie, K.
    Krejany, E.
    Gorelik, A.
    Liew, D.
    Prideaux, L.
    Lawrance, I.
    Andrews, J.
    Bampton, P.
    Jakobovits, S.
    Florin, T.
    Gibson, P.
    Debinski, H.
    Gearry, R.
    Macrae, F.
    Samuel, D.
    Kronborg, I.
    Radford-Smith, G.
    Selby, W.
    Johnston, M.
    Woods, R.
    Elliott, P. R.
    Bell, S.
    Brown, S.
    Connell, W.
    Desmond, P.
    Singh, S.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S373 - S373
  • [28] Preventing Crohn's Disease Recurrence After Resection With Adalimumab: Role of Drug and Anti-Drug Antibody Levels
    Wright, Emily K.
    Kamm, Michael A.
    Selvaraj, Fabiyola
    Princen, Fred
    De Cruz, Peter
    Hamilton, Amy L.
    Ritchie, Kathryn
    Krejany, Efrosinia O.
    Gorelik, Alexandra
    Liew, Danny
    Prideaux, Lani
    Lawrance, Ian C.
    Andrews, Jane M.
    Bampton, Peter A.
    Jakobovits, Simon
    Florin, Tim
    Gibson, Peter R.
    Debinski, Henry
    Gearry, Richard B.
    Macrae, Finlay A.
    Samuel, Douglas
    Kronborg, Ian
    Radford-Smith, Graham L.
    Selby, Warwick
    Johnston, Michael J.
    Woods, Rodney
    Elliott, Peter R.
    Bell, Sally
    Brown, Steven J.
    Connell, William
    Desmond, Paul V.
    Singh, Sharat
    GASTROENTEROLOGY, 2015, 148 (04) : S849 - S849
  • [29] Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial
    Nakase, H.
    Motoya, S.
    Matsumoto, T.
    Watanabe, K.
    Hisamatsu, T.
    Yoshimura, N.
    Ishida, T.
    Kato, S.
    Nakagawa, T.
    Esaki, M.
    Nagahori, M.
    Matsui, T.
    Naito, Y.
    Kanai, T.
    Suzuki, Y.
    Nojima, M.
    Watanabe, M.
    Hibi, T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (09) : 873 - 882
  • [30] Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory
    Keating, Paula Elizabeth
    Hock, Barry D.
    Chin, Paul K. L.
    O'Donnell, John Liston
    Barclay, Murray Lindsay
    THERAPEUTIC DRUG MONITORING, 2024, 46 (05) : 619 - 626
12345